切换至 "中华医学电子期刊资源库"
高级检索
中华肺部疾病杂志(电子版)

中华肺部疾病杂志(电子版) ›› 2020, Vol. 13 ›› Issue (01) : 28 -33. doi: 10.3877/cma.j.issn.1674-6902.2020.01.006

论著

门脉高压相关性肺动脉高压临床分析
王艳1, 张向峰1,†(), 孙茜1, 张文美1, 朱光发1, 高杨1, 陈如冲2   
  1. 1. 100029　北京，首都医科大学附属北京安贞医院呼吸与危重症医学科
    2. 510120　广州，广州医科大学附属第一医院呼吸疾病国家重点实验室
  • 收稿日期:2019-11-07 出版日期:2020-02-25
  • 通信作者: 张向峰
  • 基金资助:
    国家自然科学基金资助项目(81800222); 呼吸疾病国家重点实验室开放课题(SKLRD-OP-201909)

Clinical analysis of portopulmonary hypertension

Yan Wang1, Xiangfeng Zhang1,†(), Qian Sun1, Wenmei Zhang1, Guangfa Zhu1, Yang Gao1, Ruchong Chen2   

  1. 1. Department of Respiratory and Critical Care Medicine, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China
    2. State Key Laboratory of Respiratory Diseases, First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China
  • Received:2019-11-07 Published:2020-02-25
  • Corresponding author: Xiangfeng Zhang
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

王艳, 张向峰, 孙茜, 张文美, 朱光发, 高杨, 陈如冲. 门脉高压相关性肺动脉高压临床分析[J]. 中华肺部疾病杂志(电子版), 2020, 13(01): 28-33.

Yan Wang, Xiangfeng Zhang, Qian Sun, Wenmei Zhang, Guangfa Zhu, Yang Gao, Ruchong Chen. Clinical analysis of portopulmonary hypertension[J]. Chinese Journal of Lung Diseases(Electronic Edition), 2020, 13(01): 28-33.

目的

探讨门脉高压相关性肺动脉高压(PoPH)的临床特点和经胸超声心动测量右心房线性指数同心功能或肝功能的关系。

方法

选择首都医科大学附属北京安贞医院呼吸与危重症医学科2012年1月至2018年12月收治的门脉高压相关性肺动脉高压患者11例，回顾性分析11例患者的临床症状和体征、影像检查资料、实验室检查结果、右心导管检查测算数据、心肺功能测定结果、治疗和转归等。所有患者进行NHYA分级与mMRC量表评分。实验室检查结果包括血常规、生化、凝血、B型脑钠肽、动脉血气分析等，用以计算Child-Pugh及MELD等评分。

结果

11例中男性5例，女性6例，肝硬化门脉高压者9例，非肝硬化门脉高压者2例，追溯病史发现肺动脉高压距离门脉高压诊断时间为0.5至19年，中位时间5年。NHYA分级与改良MRC呼吸困难(mMRC)评分存在正相关关系[r＝0.9608，95%CI(0.8460，0.9896), P<0.0001]，与Child-Pugh评分无相关关系。右心房线性指数与BNP存在相关关系[r＝0.7930，95%CI(0.3684，0.9439)，P＝0.0036]，与终末期肝脏疾病评分(MELD)无相关关系。所有患者均存在不同程度的低氧血症，肺泡-动脉血氧分压差值较预计值升高(t＝3.669，P＝0.0018)，具有显著性差异。就诊时已出现右心功能严重下降的患者预后差。

结论

PoPH患者多以运动性呼吸困难为首发症状，与心功能严重程度相关，与肝功能无显著线性关系，临床随访不能只评价肝功能。随访中超声心动图中右心房径线的测量有助于心功能评估。尽早干预肺动脉压力的升高，有助于右心功能的保护，改善预后。

关键词: 肝硬化, 门脉高压, 肺动脉高压, 临床分析
Objective

To explore the clinical features of portopulmonary hypertension (PoPH) and the relationship between the right atrial liner index and the heart function.

Methods

Eleven patients were diagnosed as PoPH in Beijing Anzhen Hospital, Capital Medical University in China from January 2012 to December 2018. The general information, clinical manifestation, medical imaging results, laboratory tests, right heart catheter data, cardiopulmonary exercise test, treatment and prognosis of the patients were analyzed retrospectively. The laboratory tests included the complete blood count, serum chemistry profile, coagulation function, B type brain natriuretic peptide, and arterial blood gas analysis, which were used to calculate the scales of Child-Pugh and Model for the end-stage liver disease (MELD).

Results

The patients (5 males and 6 females) aged from 29 to 85 years. Hepatocirrhosis was found in 9 cases and non-hepatocirrhosis was found in 2 cases. According to the medical history, the onset time of pulmonary hypertension was 0.5-19 years after portal vein hypertension, with the median time of 5 years. The scale of New York Heart Association (NYHA) was positively correlated with the modified Medical Research Council (mMRC) scale [r=0.9608, 95%CI (0.8460, 0.9896), P<0.0001], however, it had no correlation with Child-Pugh scale. The correlation coefficient was 0.7930 between the right atrial linear index and the BNP with the 95%CI of 0.3684-0.9439 (P=0.0036). However, no significant difference was found between the right atrial linear index and the MELD. All the patients suffered from hypoxemia. The alveolar-arterial oxygen differential pressure (PA-aO2) was higher significantly than the predicted value (t=3.669, P=0.0018). The patients with severe heart failure had poor prognosis.

Conclusion

The patients with PoPH are more likely to experience exertional dyspnea, which is associated with the degree of the heart dysfunction. And it is a fact that all the patients have hypoxemia. Therefore, the clinical decision for the patients with PoPH should not be made only in the consideration of the liver function. The right atrial linear index is an available option to follow such patients.

Key words: Liver cirrhosis, Hypertension, portal, Pulmonary hypertension, Clinical analysis
表1 POPH患者的基本情况及临床特征(n＝11)
项　目 单位 数值
年龄 岁 55(47～74)
男性 [n(%)] 4(36.4)
女性 [n(%)] 7(73.6)
体重 kg 62.36±8.27
身高 m 1.66±0.10
BMI kg/m2 22.63±2.41
原发性肝脏疾病    
  病毒性肝炎肝硬化 [n(%)] 7(63.63)
  酒精性肝炎肝硬化 [n(%)] 1(9.09)
  自身免疫性肝炎肝硬化 [n(%)] 1(9.09)
  非原发肝脏疾病    
  布加综合征 [n(%)] 1(9.09)
  门静脉闭锁 [n(%)] 1(9.09)
NYHA分级    
  Ⅱ级 [n(%)] 6(54.55)
  Ⅲ级 [n(%)] 2(18.18)
  Ⅳ级 [n(%)] 3(27.27)
mMRC评分    
  1分 [n(%)] 1(9.09)
  2分 [n(%)] 5(45.45)
  3分 [n(%)] 2(18.18)
  4分 [n(%)] 3(27.27)
Child-pugh分级    
  A级 [n(%)] 2(18.18)
  B级 [n(%)] 7(63.63)
  C级 [n(%)] 2(18.18)
图1 右心房线性指数、BNP及MELD评分的多元相关分析，*：P<0.05
表2 PoPH患者超声心动图结果、MELD评分及BNP数值
序 右心房短径mm 右心房长径mm 右心房面积cm2 TRVa cm/s 估测sPAP mmHg BSA m2 右心房线性指数cm/m2 MELD评分 BNP pg/ml
1 39 56 21.8 480 100 1.62 3.46 11 150
2 52 59 30.7 347 55 1.72 3.44 14 162
3 57 64 36.5 417 86 1.98 3.23 11a 374
4 41 52 21.3 366 79 1.47 3.54 9 128
5 43 53 22.8 379 63 1.60 3.31 13 969
6 51 54 27.5 436 85 1.77 3.05 13 72
7 50 64 32.0 342 85 1.53 4.20 11 1 570
8 57 66 37.6 426 63 1.56 4.22 10 1 788
9 50 60 30.0 367 64 1.80 3.33 11 466
10 54 67 36.2 370 67 1.72 3.90 9 1 219
11 44 57 25.1 290 42 1.85 3.08 12 686
49 59 29.2 383 72 1.69 3.52 11 689
SD 6 5 60.0 54 13 0.15 0.41 2 613
图2 门脉高压相关性肺动脉高压患者胸腹部CT表现；注：A增粗的主肺动脉横径大于同层面升主动脉横径；B增大的右心房(右箭头)及右心室，增粗的右肺下叶动脉(上箭头)；C缩小且比例失调的肝脏(右箭头)，表明凹凸不平，增大的脾脏(左箭头)；D增粗的左肾静脉(下箭头)汇入下腔静脉(右箭头)
表3 3例PoPH患者的右心导管结果
序号 RAP mmHg mPAP mmHg POAP mmHg PVR Dny·s/cm5 CO L/min CI L/min/m2
1 6/1 30 2 789.47 3.04 1.86
2 8/0 36 6 591.99 4.86 2.89
3 10/1 36 15 449.49 6.40 3.22
图3 肺泡血氧梯度t检验箱式图；注：D(A-a)O2：肺泡动脉血氧差值，D(A-a)O2 Pred：肺泡动脉血氧差值预计值；*：二者存在统计学差异
表4 POPH患者动脉血气分析结果(n＝11)
序号 PaCO2 mmHg PaO2 mmHg D(A-a)O2a mmHg D(A-a)O2 Predb mmHg
1 25.0 67.7 50.8 14.1
2 31.4 92.6 17.9 12.6
3 24.7 72.1 46.8 12.6
4 31.3 76.8 33.8 14.7
5 37.4 68.1 34.9 14.3
6 40.6 80.6 18.4 10.7
7 26.2 79.2 37.8 17.4
8 25.5 59.3 58.6 8.6
9 36.5 99.1 5.0 19.7
10 33.6 84.2 23.5 20.4
11 30.3 83.8 28.1 12.4
31.1 78.5 32.3 14.3
s 5.5 11.5 15.9 3.6
1
Galie N, Humber M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension[J]. Eur Heart J, 2016, 37(1): 67-119.
2
Hoeper MM, Bogaard HJ, Condliffe R, et al. De finitions and diagnosis of pulmonary hypertension[J]. J Am Coll Cardiol, 2013, 62(Suppl 25): D42-D50.
3
Simón-Talero M, Roccarina D, Martínez J, et al. Association between portosystemic shunts and increased complications and mortality in patients with cirrhosis[J]. Gastroenterology, 2018, 154(6): 1694-1705.
4
Le Pavec J, Souza R, Herve P, et al. Portopulmonary hypertension: survival and prognostic factors[J]. Am J Respir Crit Care Med, 2008, 178(6): 637-643.
5
Sasiharan S, Arun N, Loqan T, et al. Survival in portopulmonary hypertension: outcomes of the United Kingdom National pulmonary arterial hypertension registry[J]. J heart and lung transplant, 2017, 36(7): 770-779.
6
ColleI O, Moreau R, Godinho E, et al. Diagnosis of portopulmonary hypertension in candidates for liver transplantation: a prospective study[J]. Hepatology, 2003, 37(2): 401-409.
7
Chen HS, Xing SR, Xu WG, et al. Portopulmonary hypertension in cirrhotic patients: Prevalence, clinical features and risk factors[J]. Exp Ther Med, 2013, 5(3): 819-824.
8
Hervé P, Lebrec D, Brenot F, et al. Pulmonary vascular disorders in portal hypertension[J]. Eur Respir J, 1998, 11(5): 1153-1166.
9
Herve P, Le Pavec J, Sztrymf B, et al. Pulmonary vascular abnormalities in cirrhosis[J]. Best Pract Res Clin Gastroenterol, 2007, 21(1): 141-159.
10
Tilg H, Wilmer A, Vogel W, et al. Serum levels of cytokines in chronic liver diseases[J]. Gastroenterology, 1992, 103(1): 264-274.
11
Miot-Noirault E, Faure L, Guichard Y, et al. Scintigraphic in vivo assessment of the development of pulmonary intravascular macrophages in liver disease: experimental study in rats with biliary cirrhosis[J]. Chest, 2001, 120(3): 941-947.
12
Hervé P, Lebrec D, Brenot F, et al. Pulmonary vascular disorders in portal hypertension[J]. Eur Respir J, 1998, 11(5): 1153-1166.
13
Roberts KE, Fallon MB, Krowka MJ, et al. Pulmonary Vascular Complications of Liver DiseaseStudy Group. Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease[J]. Am J Respir Crit Care Med, 2009, 179(9): 835-842.
14
Nunes H, Lebrec D, Mazmanian M, et al. Role of nitric oxide in hepatopulmonary syndrome in cirrhotic rats[J]. Am J Respir Crit Care Med, 2001, 164(5): 879-885.
15
Schraufnagel DE, Kay JM. Structural and pathologic changes in the lung vasculature in chronic liver disease[J]. Clin Chest Med, 1996, 17: 1-15.
16
Guido M, Sarcognato S, Sacchi D, et al. Pathology of idiopathic non-cirrhotic portal hypertension[J]. Virchows Arch, 2018, 473(1): 23-31.
17
Nikolic I, Yung LM, Yang PR, et al. Bone morphogenetic protein 9 Is a mechanistic biomarker of portopulmonary hypertension[J]. Am J Respir Crit Care Med, 2019, 199(7): 891-902.
18
Rodríguez-Roisin R, Krowka MJ, Agustí A. Hepatopulmonary disorders：gas exchange and vascular manifestations in chronic liver disease[J]. Comp Phys, 2018, 8(2): 711-729.
19
Finkelhor RS, Lewis SA, Pillai D, et al. Limitations and strengths of doppler/echo pulmonary artery systolic pressure-right heart catheterization correlations: a systematic literature review[J]. Echocardiography, 2014, 32(1): 10-18.
20
Hua R, Sun YW, Wu ZY, et al. Role of 2-dimensional doppler echo-cardiography in screening portopulmonary hypertension in portal hypertension[J]. Hepatobiliary Pancreat Dis Int, 2009, 8(2): 157-161.
21
Maceira AM, Cosín-Sales J, Roughton M, et al. Reference right atrial dimensions and volume estimation by steady state free precession cardiovascular magnetic resonance[J]. J Cardiovasc Magn Reson, 2013, 15(1): 29-38.
22
Raymond RJ, Hinderliter AL, Willis PW, et al. Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension[J]. J Am Coll Cardiol, 2002, 39(7): 1214-1219.
23
Bustamante LM, Perrone S, De La Fuente RL, et al. Right atrial size and tricúspide regurgitation severity predict mortality or transplantation in primary pulmonary hypertension[J]. J Am Soc Echocardiogr, 2002, 15: 1160-1164.
24
AbuHalimeh B, Krowka MJ, Tonelli AR. Treatment barriers in portopulmonary hypertension[J]. Hepatology, 2019, 69(1): 431-443.
25
Farber HW, Miller DP, Poms AD, et al. Five-year outcomes of patients enrolled in the REVEAL registry[J]. Chest, 2015, 148(4): 1043-1054.
26
Ghofrani HA, Galiè N, Grimminger F, et al. Riociguat for the treatment of pulmonary arterial hypertension[J]. N Engl J Med, 2013, 369(4): 330-340.
27
Cosarderelioglu C, Cosar AM, Gurakar M, et al. Portopulmonary hypertension and liver transplant: recent review of the literature[J]. Experimental and Clinical Transplantation, 2016, 14(2): 113-120.
28
Hollatz TJ, Musat A, Westphal S, et al.Treatment with sildenafil and treprostinil allows successful liver transplantation of patients with moderate to severe portopulmonary hypertension[J]. Liver Transpl, 2012, 18(6): 686-695.
29
Raevens S, De Pauw M, Reyntjens K, et al. Oral vasodilator therapy in patients with moderate to severe portopulmonary hypertension as a bridge to liver transplantation[J]. Eur J Gastroenterol Hepatol, 2013, 25(4): 495-502.
30
Krowka MJ, Swanson KL, Frantz RF, et al. Portopulmonary hypertension：results from a 10-year screening algorithm[J]. Hepatology, 2006, 44(6): 1502-1510.
[1] 李建美, 邓静娟, 杨倩. 两种术式联合治疗肝癌合并肝硬化门静脉高压的安全性及随访评价[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 41-44.
[2] 吴方园, 孙霞, 林昌锋, 张震生. HBV相关肝硬化合并急性上消化道出血的危险因素分析[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 45-47.
[3] 莫闲, 杨闯. 肝硬化患者并发门静脉血栓危险因素的Meta分析[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 678-683.
[4] 熊锋, 娄建丽. 慢性阻塞性肺疾病急性加重期预后的临床分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 550-553.
[5] 代芬, 卞士柱. 无创机械通气联合肺康复在肺动脉高压呼吸衰竭治疗中的临床应用[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 560-562.
[6] 张七妹, 麦宜准, 蒋浩波. 喘可治对慢性阻塞性肺疾病缓解期的临床分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 578-580.
[7] 韩宇, 张武, 李安琪, 陈文颖, 谢斯栋. MRI肝脏影像报告和数据系统对非肝硬化乙肝患者肝细胞癌的诊断价值[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 669-673.
[8] 李勇, 兰川, 吴斌, 张光年, 李敬东. 术前血小板-白蛋白评分对肝硬化肝癌术后预后的预测价值[J]. 中华肝脏外科手术学电子杂志, 2023, 12(04): 412-416.
[9] 许语阳, 吕云福, 王葆春. 乙肝后肝硬化门静脉高压症脾肿大外科治疗进展[J]. 中华肝脏外科手术学电子杂志, 2023, 12(04): 469-473.
[10] 秦维, 王丹, 孙玉, 霍玉玲, 祝素平, 郑艳丽, 薛瑞. 血清层粘连蛋白、Ⅳ型胶原蛋白对代偿期肝硬化食管胃静脉曲张出血的预测价值[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 447-451.
[11] 张雯, 宋牡丹, 邓雪婷, 张云. 强化营养支持辅助奥曲肽治疗肝硬化合并食管胃底静脉曲张破裂出血的疗效及再出血危险因素[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 456-460.
[12] 朱翔宇, 王建美, 张辉, 叶红英. 无创左心室压力-应变循环技术在左心室功能参数与肝硬化的相关性分析[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 494-498.
[13] 郭亮亮, 邱珊珊, 钟萍, 赵心恺. 血小板-白蛋白-胆红素评分对肝硬化上消化道出血的诊断价值[J]. 中华消化病与影像杂志(电子版), 2023, 13(04): 216-219.
[14] 孔凡彪, 杨建荣. 肝脏基础疾病与结直肠癌肝转移之间关系的研究进展[J]. 中华临床医师杂志(电子版), 2023, 17(07): 818-822.
[15] 余林阳, 王美英, 李建斌, 楼骁斌, 谢思远, 马志忠, 齐海英, 李稼. 高原地区肺炎合并右心功能衰竭体征患儿的肺动脉压力和心脏形态与功能的特征[J]. 中华临床医师杂志(电子版), 2023, 17(05): 535-544.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号